Casio Computer Co. will soon release the GM-B2100GD-9A, which features a full-metal design with an iconic octagonal bezel, as the latest addition to the G-SHOCK brand of shock-resistant watches.
The 2100 line, now offered in a stunning new yellow-gold hue with the GM-B2100GD-9A, has a distinctive octagonal bezel and slim, simple design that has proven to be globally popular.
The new GM-B2100GD-9A has a yellow-gold IP not only to the bezel and band but even to minute facets of the design such as the side buttons and screws.
Accents in a hue similar to yellow gold are applied to highlight components, including the index marks and hands, that stand out against the black dial, giving the watch a chic impression.
The new watch offers practical value with its Tough Solar charging mechanism that does away with the need to frequently change the battery. Also, it has the Mobile Link feature*, which when coupled with a Bluetooth-enabled smartphone, allows for a precise timekeeping display, simple alarm setting, world time setting, and other capabilities.
The new watch goes on sale on March 10.


Oil Prices Hold Near Highs as U.S.-Iran Conflict Escalates
Gulf Ministers to Meet Iran in Oman Over Hormuz Shipping Deal
Japan Producer Inflation Eases to 7.6% in August
White House Weighs Refined Copper Tariffs as Cost Concerns Grow
Australia Plans New Rules Giving Users Control Over Social Media Feeds
Brazil Court Suspends Sigma Lithium Mine Operations
Office design isn’t keeping up with post-COVID work styles - here’s what workers really want
The pandemic is still disrupting young people’s careers
Iraq Seeks 6 Million Bpd OPEC+ Oil Quota
Why a ‘rip-off’ degree might be worth the money after all – research study
Norway Core Inflation Rises to 3% in August
Yes, government influences wages – but not just in the way you might think
The American mass exodus to Canada amid Trump 2.0 has yet to materialize
Gold Prices Steady as Hot PPI Boosts Fed Rate Hike Bets
Asian Currencies Steady as Yen Holds Firm, Oil Tops $100
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial 



